Trek Therapeutics in the News

October, 2017 – Pharmafocus Article: Securing the Cold Chain with New Solutions


August 21, 2017 – Milano Finanza Article: Ambrosus signs Agreement with Trek for Blockchain Protocol


July, 2017 – HCV Patient Access: Trek Therapeutics Takes the Road Less Traveled


May, 2017 – Article: “Dancing to the Same Tune?” in Trends in Patient Centricity


April 20, 2017 – Eyeforpharma Interview with Ann Kwong, Part I


April 20, 2017 – Eyeforpharma Interview with Ann Kwong, Part II


Mar 2, 2017 – Article: “A Marriage Made in Heaven” at


Dec 14, 2016 – STAT Interview with Trek Therapeutics CEO Ann Kwong
Nov 3, 2016 – Washington Post feature article

Press Releases

Feb 13, 2017 -Trek Therapeutics Announces Oral Presentation of Faldaprevir, TD-6450 and Ribavirin Ph2a Trial Results at the Asian Pacific Association for the Study of the Liver on February 18, 2017 in Shanghai
Sep 15, 2016 – Interim Results from Trek Therapeutics’ Phase 2 Study Show Triple Combination Therapy Achieves 100% SVR4 in Genotype 4 HCV Patients
Aug 17, 2016 – Medivir Licenses Rights to MIV-802 to Trek Therapeutics


Jul 26, 2016 -Trek Therapeutics Acquires Two Antiviral Inhibitors From Vertex Pharmaceuticals
Jun 21, 2016 -Trek Therapeutics Initiates Phase 2a Study of Faldaprevir and TD-6450, With and Without Ribavirin, in Patients with HCV GT 1b
Oct 27, 2015 – Theravance Biopharma and Trek Therapeutics Announce Initiation of Phase 2a Trial of TD-6450, an NS5A Inhibitor to Treat Hepatitis C

Presentations/Publications by Trek-affiliated Members

HEP DART 2015, December 6-10, Wailea, USA
Price and Affordability of Hepatitis C Drugs: How Did We Get Into This Mess? (Cami Graham, MD, MPH)
Eliminating HCV: Why Highly Effective Drugs Are Not Enough (Ann Kwong, PhD)